RLT Roundtables
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The third part of this roundtable explores imaging interpretation and toxicity management.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.